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Safety of Aggressive Lipid Management
Michael H. Davidson, MD, FACC,* Jennifer G. Robinson, MD, MPH†
Chicago, Illinois; and Iowa City, Iowa
Data from recent clinical trials of high- versus moderate-dose statin therapy support the recommendation to
achieve a low-density lipoprotein (LDL) 100 mg/dl in high-risk patients and reveal that many patients will re-
quire a high-dose statin to achieve this goal. Overall, low rates of serious musculoskeletal (0.6%) and hepatic
(1.3%) toxicity have been observed with high-dose statin therapy. In the long-term trials, atorvastatin 80 mg
had higher rates of persistent transaminase elevations but rates of myopathy and rhabdomyolysis similar to
lower doses of statins. The rate of myopathy and rhabdomyolysis for simvastatin 80 mg, although still low, was
about 4 higher than for atorvastatin 80 mg and lower doses of statin. A similar margin of safety would be ex-
pected in properly selected patients with characteristics similar to those who participated in the clinical trials.
High-dose statin therapy or combination therapy will be required for the large majority of very high-risk patients
to achieve the optional LDL goal of 70 mg/dl. While the combination of ezetimibe, bile-acid sequestering
agents, niacin, and fenofibrate with moderate dose statins appears to be reasonably safe, the long-term safety
of combination with high-dose statins remains to be established. In order to optimize patient outcomes, clini-
cians should be aware of specific patient characteristics, such as advancing age, gender, body mass index, or
glomerular filtration rate, which predict muscle and hepatic statin toxicity. (J Am Coll Cardiol 2007;49:
1753–62) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.01.067t
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aecent clinical trials have demonstrated additional cardio-
ascular risk reduction with high-dose compared with
oderate-dose statin therapy in subjects with coronary heart
isease (CHD) (1–4). In the trials completed to date, those
eceiving high-dose (80 mg) atorvastatin or simvastatin had
dditional 11% to 21% reductions in the relative risk of
ardiovascular events compared with those receiving a mod-
rate statin dose (40 mg of pravastatin, 20 to 40 mg of
imvastatin, or 10 mg of atorvastatin). In the high-dose
tatin groups, low-density lipoprotein (LDL) cholesterol
evels were lowered on average to 62 to 81 mg/dl; in the
oderate-dose statin groups, LDL levels were 77 to 104
g/dl. In this review, we will address several safety issues
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ccepted January 22, 2007.hat may arise when considering more aggressive LDL-
owering therapy for a given patient.
The fundamental, if obvious, requirement for considering
ore aggressive LDL-lowering is that the patient has
ufficiently elevated risk to benefit from more aggressive
reatment. The third report of the National Cholesterol
ducation Program Adult Treatment Panel (NCEP) iden-
ified an LDL goal 100 mg/dl for high-risk patients
those with clinical cardiovascular disease, diabetes, or
0-year CHD risk 20%) (5). A subsequent 2004 report
rom the NCEP suggested an optional LDL goal 70
g/dl for those at the highest risk, including those with
stablished cardiovascular disease plus additional high-risk
haracteristics: diabetes mellitus, multiple cardiovascular
isk factors, multiple risk factors of the metabolic syndrome, or
evere or poorly controlled risk factors, especially continued
igarette smoking (6). An LDL goal 100 mg/dl was also
xtended as an option to moderately high-risk primary preven-
ion patients who had 2 or more risk factors and a 10% to 20%
0-year CHD risk as well as other indicators of increased risk.
The 2004 NCEP report also recommended at least a 30%
o 40% reduction in LDL in order to significantly lower
ardiovascular risk. It should be noted, however, that many,
f not most, patients will require at least a 50% reduction in
DL to achieve an LDL 100 mg/dl. In the TNT
Treating to New Targets) trial, based on the standard
eviation of LDL at baseline, it can be estimated that
pproximately 90% of subjects in the atorvastatin 80 mg
roup had an LDL 100 mg/dl (2). Conversely, in the
w
p
t
t
N
r
t
S
(
a
r
n
t
s
t
b
d
b
p
s
c
fi
p
h
s
L
r
t
S
A
t
h
h
s
k
t
e
p
t
s
1
1
c
s
r
o
n
s
a
t
r
a
l
v
o
A
t
c
R
s
c
d
r
h
s
E
r
s
p
b
1
N
s
u
t
s
v
L
v
l
d
r
1754 Davidson and Robinson JACC Vol. 49, No. 17, 2007
Aggressive Lipid-Lowering Safety May 1, 2007:1753–62atorvastatin 10 mg group, ap-
proximately 50% of patients had
an LDL 100 mg/dl. The mean
LDL in the atorvastatin 80 mg
group in the IDEAL (Incremen-
tal Decrease in End Points
Through Aggressive Lipid Low-
ering) trial was slightly higher at
81 mg/dl so slightly fewer sub-
jects had an LDL 100 mg/dl.
Notably, less than one-half of
subjects in the atorvastatin 80 mg
arms of TNT and IDEAL
achieved the more aggressive
LDL goal 70 mg/dl. Several
conclusions can be drawn: 1)
most moderately high and high-
risk patients will require high-
dose statin or combination statin
therapy to achieve an LDL100
mg/dl, especially since subjects
with severe hypercholesterolemia
ere excluded from these trials; 2) almost all very high-risk
atients will require high-dose statin therapy or combina-
ion statin therapy to achieve an LDL 70 mg/dl; and 3)
he TNT and IDEAL trials were a validation of the
CEP III goal 100 mg/dl rather than the 2004 NCEP
eport optional LDL goal70 mg/dl. However, support for
he more aggressive goal comes from the Heart Protection
tudy (7) and a retrospective analysis of the PROVE-IT
Pravastatin or Atorvastatin Evaluation and Infection Ther-
py–Thrombolysis in Myocardial Infarction 22) trial (1).
Safety will now be examined within the context of the
equirement for high-dose statin or a statin used in combi-
ation with other lipid-lowering agents. It is very important
o note that subjects who were most likely to experience
tatin toxicity were excluded from clinical trials. Therefore,
he adverse event rates observed in clinical trials should not
e generalized to an unselected patient population. High-
ose statin monotherapy and combination therapy should
e used very cautiously in patients having characteristics that
redict statin toxicity including advanced age, small body
ize, diminished renal and hepatic function, or multiple
omorbidities or medications, and avoided if glomerular
ltration is 30 ml/min/1.73 m2. In appropriately selected
atients (i.e., similar to those participating in clinical trials),
igh-dose statins would be expected, however, to have a
imilar margin of safety (1–4,8–13) (Table 1). The National
ipid Association Statin Safety Task Force has provided
ecommendations for management of muscle-related symp-
oms in patients receiving statin therapy (10) (Table 2).
afety of Moderate-Dose Statins
lthough statins have a 40% higher rate of adverse effects
Abbreviations
and Acronyms
CHD  coronary heart
disease
CI  confidence interval
CK  creatine kinase
CYP  cytochrome
FDA  Food and Drug
Administration
HDL  high-density
lipoprotein
HR  hazard ratio
LDL  low-density
lipoprotein
NCEP  National
Cholesterol Education
Program Adult Treatment
Panel
ULN  upper limit of
normalhan placebo, the rates of significant musculoskeletal and pepatic toxicity are very low for both moderate- and
igh-dose statin therapy (14). Nonurgent adverse events
uch as myalgia (muscle aches or pain with normal creatine
inase [CK]) and a single abnormal elevated liver function
est constitute approximately two-thirds of reported adverse
vents. In a meta-analysis of over 70,000 subjects in 18
rimary and secondary prevention placebo-controlled trials,
he number needed to harm for any adverse event with
tatins was 197 versus the number needed to treat to prevent
cardiovascular event of 27 (14). In other words, treating
,000 patients would prevent 37 cardiovascular events and
ause 5 adverse events of any type. However, serious events
uch as CK 10 the upper limit of normal (ULN) or
habdomyolysis are rare and have a number needed to harm
f 3,400. Rhabdomyolysis alone was extremely rare with a
umber needed to harm of 7,428. In this analysis, fluva-
tatin, the least efficacious, also had the lowest rate of
dverse events, and atorvastatin, the most efficacious, had
he highest rate. Simvastatin, pravastatin, lovastatin, and
osuvastatin appeared to have similar odds of adverse events.
Excluding cerivastatin, post-approval surveillance reveals
rate of serious musculoskeletal toxicity no higher than the
evels observed in pre-approval clinical trials, although the
ast majority of prescriptions are for low or moderate doses
f statin. In the Food and Drug Administration’s (FDA)
dverse Event Reporting System database up until 2002,
he reporting rates per million statin prescriptions was 0.38
ases for myopathy and 1.07 cases of rhabdomyolysis (15).
ates increased for all statins after the release of rosuvastatin
uggesting changes in reporting rates rather than any
hanges in adverse effect profiles (15). An administrative
atabase analysis also reported low rates of hospitalized
habdomyolysis: 1.6 to 3.5 cases per 10,000 person-years of
ospitalized patients on statins (16).
Post-approval surveillance also shows no evidence of
erious hepatotoxicity with statins. The FDA’s Adverse
vent Reporting System database through 2004 reported a
ate of 0.69 cases of liver failure/hepatitis in per million
tatin prescriptions, similar to the rate in the general adult
opulation (15). Analysis of an administrative claims data-
ase reported 6.1 to 12.8 hospitalized hepatic events per
0,000 person-years of hospitalized patients on statins (17).
one were hospitalized within 6 months of starting their
tatin. Furthermore, only 1 of the 51,741 patients who
nderwent liver transplantation between 1990 and 2002 was
aking a marketed statin (18).
The drugs that most commonly increase the toxicity of
tatins are cyclosporine and those affecting metabolism
ia cytochrome (CYP) P450 or glucuronidation (19).
ovastatin, simvastatin, and atorvastatin are metabolized
ia the CYP P450 3A4 pathway. Fluvastatin is metabo-
ized by the CYP 2C9, and cerivastatin is metabolized by
ual 2C9 (or 2C8) and 3A4 pathways. Pravastatin and
osuvastatin are not significantly metabolized by the CYP
athway. The CYP 3A4 inhibitors most commonly re-
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May 1, 2007:1753–62 Aggressive Lipid-Lowering Safetyorted to increase the risk of myopathy and rhabdomyolysis
re erythromycin, clarithromycin, the antifungals ketocon-
zole and itraconazole, protease inhibitors indinavir, nelfi-
avir, ritonavir, and saquinavir, and nefazodone. The anti-
epressants fluoxetine, fluvoxamine, and sertraline are also
YP 3A4 inhibitors and may have the potential to increase
tatin toxicity. Diltiazem, verapamil, and amiodarone are
eak inhibitors of CYP 34A and have been reported to
ncrease the risk of myopathy with simvastatin (9). Gemfi-
rozil inhibits glucuronidation thereby increasing statin
Patient Characteristics Likely to Enhance SafetEligibility Criteria for Subjects Participating in Event Repo ting, and Pac age Inserts†
Table 1
Patient Characteristics Likely to En
Eligibility Criteria for Subjects Parti
Event Reporting, and Package Inse
Patient Characteristics‡ Sa
Age 75 yrs§
Body size Use with cau
If frail, evalu
Race/ethnicity Asian: rosuva
Statin use Prior statin u
No history of
Hepatic function No active he
ALT and AST
Renal function Creatinine 
Glomerular fi
No history of
Discontinue b
Thyroid function TSH in norma
Muscle function CK 3 ULN
Use with cau
Discontinue b
Immune function No chronic im
Cytochrome P450 inhibitors No concomit
Macrolide an
Antiviral drug
Systemic azo
Verapamil (s
Diltiazem (lo
Amiodarone
Nefazadone
Grapefruit ju
Other lipid-lowering therapy No fibrates (e
No niacin?
Alcohol intake 2 drinks pe
Avoid if alcoh
Left ventricular ejection fraction 30%
Intercurrent illness, surgery, or trauma If severe illne
medicatio
Multiple comorbidities or medications Evaluate app
*Atorvastatin 80 mg, simvastatin 80 mg, rosuvastatin 40 mg; †the ris
criterion; patients should be carefully monitored for musculoskeletal a
pressure 160/100 mm Hg, hemoglobin A1C 8.5%, hemodyna
nonmelanoma skin cancer less than 5 years ago; the relationship of t
not been established, but hypertension and diabetes were associated
§age up to 80 years at baseline in IDEAL (Incremental Decrease in En
70 years at cut-point for safety (65); other concomitant lipid-lower
higher doses of statins although reported rates of rhabdomyolysis with
when statins are used with fibrates.
ALT  alanine aminotransferase; AST  aspartate aminotransfer
thyroid-stimulating hormone; ULN  upper limit of normal.erum levels. Fenofibrate is a weaker inhibitor and does not iignificantly increase serum levels of simvastatin, pravasta-
in, or rosuvastatin.
Other very rare adverse effects such as peripheral neurop-
thy and cognitive dysfunction have been attributed to
tatins (20). In the 16 case reports of peripheral neuropathy
n patients taking statins, symptoms generally appeared
ithin 2 months of initiating statin therapy and dissipated
fter withdrawal of the statin. In clinical trials, however,
eripheral neuropathy has been found to be no more
ommon in the statin-treated group than the placebo group
igh-Dose* Statins Based ono nt Clinical Trials, Adv rse
e Safety of High-Dose* Statins Based on
ing in End Point Clinical Trials, Adverse
riterion or Characteristic/Medication to Avoid
small body frame, especially if female patient
propriate use in terms of life expectancy and goals of care
starting dose 5 mg due to decreased clearance
intolerance
isease
ULN
LN
n rate 60 ml/min/1.73 m2
otic syndrome
intravenous dye administration
e
s explanation
history of muscle disease
strenuous exercise (e.g., marathon)
suppressive therapy (especially cyclosporine)
of:
s (especially erythromycin and clarithromycin)
ecially HIV protease inhibitors)
ifungals (itraconazole and ketokonazole)
atin)
n, atorvastatin)
statin)
quart/day
lly gemfibrozil)
present
jor surgery, or major trauma, discontinue lipid-lowering
il recovered
e use in terms of life expectance and goals of care
t ratio should be carefully evaluated for patients exceeding 1 or more
epatic toxicity; ‡exclusion criteria for clinical trials also included blood
important valvular heart disease, and cancer diagnosis other than
aracteristics to increased risk of serious adverse muscle effects has
n increased risk of serious hepatic adverse effects in one study (11);
Through Aggressive Lipid Lowering); others have recommended age
rapies excluded from high-dose statin trials; limited safety data with
ate-dose statins used in combination with niacin are much lower than
 creatine kinase; HIV  human immunodeficiency virus; TSH y of Hnd P
hanc
cipat
rts†
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Aggressive Lipid-Lowering Safety May 1, 2007:1753–62ognitive function. The Heart Protection Study studied
0,536 patients over a 5-year period and found no difference
n the rate of cognitive impairment between the simvastatin
nd placebo groups (7). Nor did the PROSPER (Prospec-
ive Study of Pravastatin in the Elderly at Risk) Trial report
ny difference in cognitive function between placebo and
ravastatin therapy in patients aged 70 to 82 years (21).
afety of High-Dose Statins
hile, overall, high-dose statins were reasonably well tol-
rated in clinical trials, there was evidence of a higher rate of
dverse effects leading to their discontinuation. In the
ong-term event trials of atorvastatin 80 mg, discontinuation
ates due to unspecified drug-related adverse events were
onsistently higher in the high (7% to 10%) than moderate
ose arms (4% to 5%) over the approximately 5 years of
bservation (2,4) (Table 3). Based on these rates, fewer than
ecommendations From the National Lipid Associationtatin Safety Task orce for Muscle Issues
Table 2 Recommendations From the National Lipid AssociationStatin Safety Task Force for Muscle Issues
For Patients With Muscle Symptoms and/or an
Asymptomatic CK Elevation or Both
1. First, rule out other etiologies (including increased physical activity, trauma,
falls, accidents, seizure, hypothyroidism, infections, alcohol or drug abuse, and
rheumatologic or other muscle disorders)
2. CK monitoring
a. Obtain CK for unexplained muscle symptoms
b. May obtain baseline CK in high-risk patients, optional for others
c. No need to routinely monitor CK levels during therapy
3. Discontinue the statin if intolerable muscle symptoms occur, with or without
CK increase
a. Rechallenge with same or lower dose of same or different statin once
symptoms resolve
4. If tolerable muscle symptoms with CK 10 ULN, continue statin at same or
lower dose until symptoms dictate otherwise
5. Discontinue the statin and reconsider risk/benefit if:
a. CK 10 ULN even with tolerable muscle symptoms
b. CK 10,000 IU/l
c. Worsening serum creatinine and/or need for intravenous hydration therapy
K  creatine kinase; ULN  upper limit of normal.
eported Rates of Discontinuation of Study Medication Due to Any
Table 3 Reported Rates of Discontinuation of Study Medication
Study Treatment n
Mean Intent-to-Treat
LDL (mg/dl)
TNT Atorvastatin 10 mg 5,006 101
Atorvastatin 80 mg 4,995 77
IDEAL Simvastatin 20–40 mg 4,449 104
Atorvastatin 80 mg 4,439 81
4S Placebo 2,223 190
Simvastatin 20–40 mg 2,221 122
CARE Placebo 2,078 136
Pravastatin 40 mg 2,081 98
Atorvastatin 80 mg versus lower statin dose or active statin treatment versus control group; 4S a
his rate was not reported for other trials or only rate for muscle and/or hepatic AEs were repor
ardiovascular death; ‡nonfatal myocardial infarction, stroke, and cardiovascular death; §rate of d
ngina was not reported.
CARE  Cholesterol and Recurrent Events trial; CVD  cardiovascular disease; IDEAL  Incremental D
umbers needed to result in drug discontinuation; NNT numbers needed to treat to prevent 1 cardiovasin 20 to 1 in 50 properly selected patients would need to
iscontinue atorvastatin 80 mg therapy due to a drug-
elated adverse effect. In comparison, the number needed to
reat to prevent 1 cardiovascular event was 19 to 23 for the
trials. For the 2-year trials in patients with acute coronary
yndromes, discontinuation rates due to unspecified drug-
elated adverse effects were not reported (1,3). In the A to Z
rial, simvastatin 80 mg had a slightly higher rate of
reatment discontinuation due to muscle side effects (1.8%)
han the simvastatin 20 mg group (1.5%) (3). In the
ROVE-IT trial, the atorvastatin 80 mg group had a
lightly higher rate (1.9% vs. 1.4% in the pravastatin 40 mg
roup) of dose decreases due to side effects or abnormal liver
unction tests.
For a number of reasons, discontinuation rates in clinical
ractice could be higher if patients naive to statin therapy
re initially started on the 80 mg dose of atorvastatin or
imvastatin. Both short- and long-term statin trials ex-
luded individuals intolerant of statins, with impaired he-
atic or renal function, or receiving treatment with other
rugs that seriously affect the pharmacokinetics of statins. In
ddition, in the long-term event trials, subjects were se-
ected for ability to tolerate statins. The TNT trial had a
ead-in period with atorvastatin 10 mg during which 3.6%
f subjects were excluded due to adverse effects (2), whereas
n the IDEAL trial the large majority (75%) of subjects had
een on statin therapy before study enrollment (4). In the A
o Z trial, subjects were titrated up to 80 mg from 20 mg of
imvastatin (3). In a retrospective analysis of over 14,000
ubjects in 49 short-term trials of atorvastatin 10 mg versus
0 mg, similar rates of discontinuation due to drug-related
dverse events occurred for placebo (3%) and both doses of
torvastatin (3.5% and 1.8%, for 10 and 80 mg, respectively)
22). Unfortunately, since rates of discontinuation were not
resented separately for the 26 trials in which subjects were
andomized directly to atorvastatin 80 mg rather than
itrated, the tolerability of initiating atorvastatin at the 80
g dose compared to up-titration to the 80 mg dose cannot
-Related AE, NNH, and NNT
to Any Drug-Related AE, NNH, and NNT
ntinued Study Drug Due
Drug-Related AE (%)
NNH to Result in
Discontinuation Due
to Drug-Related AE*
NNT to Prevent 1
Event* (Any CVD
Event†/Hard Event‡)
5.3
7.2 53 19/44
4.2
9.6 19 23/60
6
6 0§ NA /10
3.5
3.2 0‡ NA /24
E were the only trials that reported discontinuations due to any drug-related adverse event (AE);
nfatal myocardial infarction, stroke, revascularization, documented or hospitalized angina, and
nuation due to AEs was higher in the placebo group; not applicable: documented or hospitalizedDrug
Due
Disco
to
nd CAR
ted; †no
iscontiecrease in End Points Through Agressive Lipid Lowering; LDL  low-density lipoprotein; NNH 
cular event; TNT Treating to New Targets; 4S Scandinavian Simvastatin Survival Study Group.
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May 1, 2007:1753–62 Aggressive Lipid-Lowering Safetye addressed from this study. However, in 1 study of over
00 dyslipidemic subjects randomized to 1 of 4 atorvastatin
oses, those who received an initial dose of atorvastatin 80
g had a treatment-related discontinuation rate of 17%
ompared with a rate of 10% to 12% for doses of 10 to 40
g (23). In a review of 4 studies where 1,393 of 1,586
ubjects were randomized directly to simvastatin 80 mg, the
iscontinuation rate due to drug-related adverse effects in
he 80-mg group (2.5%) was not significantly different
ompared to the simvastatin 40-mg group (1.9%) (24).
usculoskeletal Safety
omparisons of the rates of significant muscle and liver
dverse effects for both placebo and active-controlled statin
ardiovascular end point trials is somewhat hampered by
nconsistent reporting. With the exception of simvastatin 80
g (0.53%) (3), rates of myopathy (or myositis, defined as
K elevation 10 ULN with muscle symptoms) and
habdomyolysis were quite low (0.7%) across the range of
tatin doses, including atorvastin 80 mg, in the 7 trials for
hich these events were reported (2,4,7,25–27) (Fig. 1).
onsidered alone, rhabdomyolysis was very uncommon,
ith the highest rate (0.13%) in the simvastatin 80 mg arm
f the A to Z trial (3). Rhabdomyolysis rates in other trials
anged from 0% to 0.07% for simvastatin 20 mg to 40 mg,
ravastatin 40 mg or atorvastatin 10 mg, which was similar
o the rates of 0% to 0.06% reported for placebo-treated
ubjects (1,2,4,7,21,25–29). Although 5 cases of rhabdomy-
lysis (2 in subjects receiving atorvastatin 80 mg) were
eported by study investigators in the TNT trial, no cases of
habdomyolysis met the criteria for rhabdomyolysis defined
y the American College of Cardiology, American Heart
Figure 1 Incidence of Muscle Symptoms With CK
Elevations >10 ULN and Rhabdomyolysis
Included only cardiovascular event trials for which these data were reported
(2– 4,7,25–27). CK  creatine kinase; LDL  low-density lipoprotein; OR 
odds ratio; ULN  upper limit of normal.essociation, and National Heart, Lung, and Blood Institute
xpert panel (11). In the IDEAL trial, 2 cases of
nvestigator-reported rhabdomyolysis were reported for
imvastatin 20 to 40 mg and 2 cases for atorvastatin 80 mg;
omparison to the expert panel’s criteria was not provided
4). The 1 case of rhabdomyolysis reported in the BELLES
Beyond Endorsed Lipid Lowering with Electron Beam
omography Scanning) trial occurred after atorvastatin had
een discontinued (30). No cases of rhabdomyolysis by the
xpert panel definition were reported in any of over 29,000
ubjects in 51 other trials of atorvastatin given in doses of 10
o 80 mg (1,22,29). Elevated CK level and muscle symp-
oms consistent with the definition of myopathy given above
ccurred in 1 subject in each of the atorvastatin groups, for
rate of 0.01% in the atorvastatin 10 mg group and 0.02%
n the atorvastatin 80 mg group. In contrast, in the
re-marketing database for simvastatin 80 mg, the rate of
yopathy was 0.6% (24), similar to the rate observed in the
to Z trial (9). No cases of rhabdomyolysis were reported
n these trials.
Rates of less serious muscle complaints such as myalgia
defined as muscle ache or pain), or CK elevations 10 
LN with or without muscle symptoms were rarely re-
orted in the event trials. In the review of 49 atorvastatin
rials noted above, treatment-related myalgia occurred at a
imilar rate of 1.4% and 1.5% in subjects receiving 10 or 80
g of atorvastatin compared with a rate of 0.7% with
lacebo (22). Persistent CK 10 ULN without muscle
ymptoms was reported in 2 of 4,798 subjects (0.06%) who
eceived atorvastatin 80 mg and none of the subjects
eceiving atorvastatin 10 mg or placebo. A retrospective
nalysis of safety from the PROVE-IT trial further suggests
dverse effects are not related to LDL level (31). Adverse
uscle, hepatic, and other adverse effects were found to
ccur at the same rate across the range of on-treatment
DL levels, including very low levels 40 mg/dl.
The reason for the very low rate of myopathy for
torvastatin 80 mg remains speculative. Atorvastatin has a
ery low rate of renal clearance (2%) (10), and therefore
he pharmacokinetics would not be adversely affected in
atients with renal impairment, which is not uncommon in
high-risk CHD population (32). Although atorvastatin is
etabolized by CYP P450 3A4, inhibition of this pathway
ay not increase HMG CoA inhibition since net activity
emains unchanged (33). The majority of cases of statin-
elated rhabdomyolysis have occurred when combined with
emfibrozil (34). Fewer reports of rhabdomyolysis with
torvastatin may be the result of lower plasma exposure after
oadministration with gemfibrozil than occurs for other
tatins (35). The higher rate of myopathy and rhabdomy-
lysis for simvastatin may result in part from a decreased
ate of plasma clearance in older compared with younger
ersons (9). Age does not appear to affect clearance rates for
ither atorvastatin or rosuvastatin (8,10).
HA
c
v
p
p
(
f
(
w
1
i
e
e
d
e
t
i
o
h
I
e
w
s
a
w
h
s
c
2
t
t
s
s
d
l
e
t
c
f
a
a
p
n
l
C
I
s
c
o
i
a
a
a
1
h
8
t
0
s
S
O
a
8
2
I
t
l
s
m
c
L
a
c
t
e
a
s
R
N
p
i
t
c
1758 Davidson and Robinson JACC Vol. 49, No. 17, 2007
Aggressive Lipid-Lowering Safety May 1, 2007:1753–62epatic Safety
lthough presentation of adverse event data again were not
onsistent across all the statin trials, 3 of 4 trials of high-
ersus moderate-dose statin therapy (2–4) and the largest
lacebo controlled statin trial (7) did present data on
ersistent significant elevations of hepatic transaminases
alanine aminotransferase [ALT] or aspartate aminotrans-
erase 3 ULN on 2 or more consecutive occasions)
Fig. 2). Although the rates of hepatic enzyme elevation
ere still quite low (1.3%), achieving LDL levels below
00 mg/dl with 80 mg of atorvastatin or simvastatin resulted
n a logarithmic increase in persistent hepatic enzyme
levations compared with lower doses of statins. These
levations were reversible; reduction in the dose or with-
rawal of the statin resulted in a return of the elevated
nzyme levels to normal.
In a review of over 14,000 patients in 49 trials lasting up
o 52 months, cholecystitis and cholelithiasis were reported
n 0.25% of subjects receiving atorvastatin 10 mg and 0.29%
f subjects receiving atorvastatin 80 mg (22). No cases of
epatitis were reported with atorvastatin 10 mg (n 7,258).
n the 5 subjects diagnosed with hepatitis as an adverse
vent in the atorvastatin 80 mg group (n  4,798), 4 cases
ere considered to be treatment related. The onset of
ymptoms occurred on average 4 weeks (range 1 to 8 weeks)
fter treatment initiation, and all cases resolved within 4
eeks of atorvastatin discontinuation. One case of acute
epatitis was reported in 1,586 subjects who received
imvastatin 80 mg in pre-marketing studies (24), but no
ases of severe hepatobiliary disease were reported for the
,265 subjects who received simvastatin 80 mg for 2 years in
he A to Z trial (3).
In clinical practice, baseline elevations of hepatic
ransaminases 3 ULN are not a contraindication to
tatin therapy. Many patients with diabetes, metabolic
yndrome, or obesity will have nonalcoholic fatty liver
Figure 2 Incidence of ALT Elevations >3 ULN
on 2 or More Consecutive Occasions
Included only cardiovascular event trials for which these data were reported
(2– 4,7). Abbreviations as in Figure 1.Aisease, or nonalcoholic steatohepatitis, with transaminase
evels fluctuating between 1.5 and 3 ULN (36). After
stablishing that no other etiologies are responsible for the
ransaminase elevations, a statin at a low-to-moderate dose
an be started with close monitoring of alanine aminotrans-
erase levels. Statin dose can be titrated upward, and
dditional LDL-lowering therapies can be added as toler-
ted, although in general niacin should be avoided in these
atients due to concerns about hepatotoxicity. Transami-
ase level elevations due to fatty liver often improve with
ong-term statin therapy (37).
ancer
n a prospective meta-analysis of 14 trials of moderate-dose
tatin therapy, statin-treated subjects had the same rates of
ancer as those receiving placebo over a period of follow-up
f up to 6 years (hazard ratio [HR] 1.0 [95% confidence
nterval (CI) 0.95 to 1.06]) (38). Cancer rates in the
pproximately 5-year TNT trial were slightly higher in the
torvastatin 80 mg than in the atorvastatin 20 mg groups,
lthough this did not reach statistical significance (HR 
.13 [95% CI 0.83 to 1.55, p  0.42]) (2). Reassuringly,
owever, cancer rates were slightly lower in the atorvastatin
0 mg group compared with the simvastatin 20 to 40 mg in
he IDEAL trial (HR 0.89 [95% CI 0.68 to 1.16], p 
.38), although again not reaching statistical significance,
upporting a chance finding in the TNT trial (4).
afety of Other Agents That Lower LDL >50%
n the basis of package insert information, only a few
gents lower LDL cholesterol by 50%: atorvastatin 40 to
0 mg/day, rosuvastatin 20 to 40 mg/day, and simvastatin
0 to 80 mg combined with ezetimibe 10 mg/day (8,10,39).
n both the TNT and IDEAL trials, despite recommenda-
ions for all clinical trial participants to follow a cholesterol-
owering diet and a 50% reduction in LDL with atorva-
tatin 80 mg, fewer than half of patients had an LDL 70
g/dl. Many patients will therefore require further lifestyle
hanges as well as the addition of a second, or even third,
DL-lowering drug to achieve an LDL 70 mg/dl. Ther-
peutic lifestyle changes (including stanol or sterol-
ontaining products and increased soluble fiber intake added
o restrictions in saturated and trans fats and cholesterol),
zetimibe, bile acid sequestrants, or niacin2 g can provide
n additional 10% to 20% LDL reduction in those on a
table dose of statin (5,40–44).
osuvastatin
o cardiovascular end point studies have yet been com-
leted for rosuvastatin preventing long-term safety compar-
sons with 80 mg of simvastatin or atorvastatin. Ongoing
rials are evaluating 10 to 20 mg doses of rosuvastatin
ompared with placebo (45,46). In the open-label
STEROID (Effect of Very High-Intensity Statin Ther-
a
w
3
o
g
A
d
e
I
p
d
s
a
s
2
l
d
h

o
s
a
w
R
s
t
m
p
i
c
l
r
h
P
s
d
c
h
i
E
b
r
C
E
y
t
[
t
A
P
s
L
s
i
r
s
m
e
L
d
s
v
e
s
s
f

(

1
w
a
w
s
N
h
c
L
u
a
A
a
t
s
l
h
e
i
t
e
n
r
p
r
l
s
n
N
m
c
1
d
o
c
o
c
e
1759JACC Vol. 49, No. 17, 2007 Davidson and Robinson
May 1, 2007:1753–62 Aggressive Lipid-Lowering Safetypy on Regression of Coronary Atherosclerosis) trial, in
hich 507 patients received rosuvastatin 40 mg for 2 years,
.7% discontinued therapy due to drug-related muscle pain
r weakness, a rate higher than in the atorvastatin 80 mg
roup in the IDEAL trial (2.2%) (4,47). All subjects in the
STEROID trial were statin-naive although the open-label
esign may have influenced patient reports of adverse
vents, a phenomenon that may also have occurred in the
DEAL trial. No ASTEROID trial participant experienced
ersistent CK elevations 10 ULN, myopathy, or rhab-
omyolysis. Persistent ALT elevations were noted in only 1
ubject (0.2%).
In regard to efficacy, rosuvastatin provides approximately
n 8% additional lowering of LDL compared with atorva-
tatin, rosuvastatin at the same mg dose (48). Rosuvastatin
0 mg lowers LDL on average by about 52%, and 40 mg
owers LDL by 59% (49). With over 10,000 subjects in the
rug development program, rosuvastatin has been shown to
ave rates of myopathy and liver function abnormalities of
0.1% at doses of up to 40 mg (50). No cases of hepatitis
r liver failure were reported. Proteinuria occurred at the
ame rate as other statins at higher doses, and renal function
ctually improved (51). The 80 mg dosage of rosuvastatin
as not approved due to an excess of rhabdomyolysis.
osuvastatin has different pharmacokinetic properties than
imvastatin and atorvastatin, which may have the potential
o reduce musculoskeletal toxicity (52), although this re-
ains to be proven in long-term clinical trials in a wider
atient population. Some reassurance of safety can be found
n the fact that over one-third of subjects in the rosuvastatin
linical database were over age 65 years and had significant
evels of comorbidities or renal impairment (53). While
osuvastatin has a long half-life similar to atorvastatin, it has
ydrophilicity similar to pravastatin and no significant CYP
450 interactions. However, gemfibrozil and cyclosporine
till significantly increase rosuvastatin blood levels, and the
ose of rosuvastatin should not exceed 10 mg when used in
ombination with these drugs. Persons of Asian ancestry
ave been found to have altered pharmacokinetics resulting
n higher blood levels of rosuvastatin than persons of
uropean ancestry (8). In such patients, rosuvastatin should
e initiated at the 5 mg dosage and carefully titrated as
equired to maximum dose of 20 mg daily.
ombination Therapies
zetimibe. Again, no long-term event trial data is available
et for ezetimibe used in combination with a statin, al-
hough several trials are ongoing (IMPROVE-IT
IMProved Reduction of Outcomes], Vytorin Efficacy In-
ernational Trial, SEAS [Simvastatin and Ezetimibe in
ortic Stenosis], and SHARP [Study of Renal and Heart
rotection]). Ezetimibe coadministered with or added to
tatin therapy results in additional 15% to 20% reductions in
DL (54,55). Ezetimibe coadminstered with doses ofimvastatin 20 mg or atorvastatin 10 mg results in approx- dmately 50% reductions in LDL, and an additional 5%
eduction in LDL with each subsequent doubling of the
tatin dose. In a pooled analysis, ezetimibe simvastatin 80
g on average resulted in a 57% reduction in LDL, and
zetimibe  atorvastatin 80 mg in 60% reduction in
DL (55).
Ezetimibe  simvastatin resulted in a similar rate of
iscontinuance related to treatment compared with simva-
tatin monotherapy. No differences in muscle-related ad-
erse events were found between 4,558 subjects receiving
zetimibe  simvastatin and 2,563 subjects who received
imvastatin alone in an analysis of 17 12-week trials in the
ponsor’s database (56). Nor was any difference found in
ollow-up for as long as 48 weeks. Creatine kinase elevations
10 ULN with muscle symptoms occurred only rarely
0.1%) with either therapy. Hepatic enzyme elevations
3 ULN on 2 or more consecutive occasions occurred in
.4% of 925 ezetimibe  statin-treated subjects compared
ith 0.4% of 936 statin-only subjects (55). However, in an
dministrative database, hospitalization for hepatic events
as no higher for statin  ezetimibe combinations than for
tatin monotherapy (16).
iacin. Although niacin in doses of 1.0 to 1.5 g improves
igh-density lipoprotein (HDL) cholesterol and the total
holesterol/HDL cholesterol ratio, it does not improve
DL cholesterol when added to low-dose statin therapy
nless larger doses are given (57). Niacin 2 g lowers LDL by
n additional 9% to 24% when added to a statin (42–44).
n adverse effect profile limits widespread use of niacin,
lthough cutaneous effects are somewhat diminished with
he use of extended-release formulations. The dose of niacin
hould not exceed 2 g per day for extended-release formu-
ations because of reports of fulminant hepatotoxicity with
igher doses of sustained-release niacin. Although a propri-
tary formulation of extended-release niacin and lovastatin
s available, the maximum LDL-lowering LDL reduction
hat can be achieved is 42% with lovastatin 40 mg 
xtended-release niacin 2,000 mg (43). Extended-release
iacin combined with lovastatin has higher rates of dose-
elated persistent elevated liver function tests (1%) com-
ared with lovastatin alone (0.2%) (44). Myopathy and
habdomyolysis have been reported with the combination of
ovastatin and niacin 1 g per day, although in clinical
tudies of 1,079 subjects who received extended-release
iacin/lovastatin (Advicor, Kos Pharmaceuticals, Cranbury,
ew Jersey), no cases of rhabdomyolyis and 1 case of
yopathy were reported. The HATS Study (High-density
holesterol Atherosclerosis Treatment Study) randomized
60 subjects to placebo or to simvastatin  niacin (mean
oses of simvastatin 13 mg and niacin 2.4 g) (58). No cases
f persistent ALT or CK elevations were found, and no
ases of myopathy or rhabdomyolysis were reported. The
ngoing AIM-HIGH (Niacin Plus Statin to Prevent Vas-
ular Events) trial will evaluate whether the addition of
xtended-release niacin to simvastatin will result in a car-
iovascular risk reduction greater than expected due to the
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Aggressive Lipid-Lowering Safety May 1, 2007:1753–62egree of LDL lowering. Little data are available on the
afety of extended-release niacin when added to high doses
f simvastatin, atorvastatin, or rosuvastatin (59). The pre-
cribing information for all 3 statins advises carefully weigh-
ng the benefit of further lipid alterations against the
otential risk for combination therapy, especially with doses
f niacin 1 g per day (8–10).
ile-acid binding agents. The bile-acid binding agent,
olesevelam 2.3 to 3.8 g, lowers LDL by an additional 8% to
6% when added to statin monotherapy (60). Colsevelam
as several advantages over older bile-acid binding agents:
ewer gastrointestinal side effects, minimal interference with
he absorption of other drugs, and can be taken as 6 large
ablets daily. Bile-acid binding agents are not systemically
bsorbed and therefore have no effect on muscle or liver.
ile-acid binding agents should be used with caution when
riglyceride levels exceed 300 mg/dl since they can markedly
xacerbate hypertriglyceridemia.
ibrates. Fibrates are generally not considered effective
DL-lowering therapy and so should not be considered as
dd-on therapy for more aggressive LDL reduction. Addi-
ion of a fibrate could be considered in order to achieve more
ggressive non-HDL goals and in those patients with severe
ypertriglyceridemia (500 mg/dl) (38). Historically, how-
ver, fibrate combination therapy has been the greatest
ource of safety concerns for statin therapy. In the FDA’s
dverse Event Reporting System database, 38% of all
eported statin rhabdomyolysis cases occurred with statin 
brate combinations, although the risk associated with
emfibrozil appears to be about 15 higher than for
enofibrate when used with statins other than cerivastatin
20,34,61). Gemfibrozil has been shown to inhibit statin
lucuronidation, a second pass effect for the hepatic metab-
lism of statins. Gemfibrozil is also an inhibitor of CYP
450 2C8, a major pathway for the metabolism of ceriva-
tatin and other drugs such as pioglitazone and repaglinide.
he net result is that gemfibrozil causes a 50% to 3-fold
ncrease in statin areas under the curve, which most likely
xplains the increased propensity of the combination to cause
yopathy (62). As statin doses escalate to achieve more
ggressive LDL and non-HDL targets, combination with a
brate will likely cause a multiplicative increase in the rate of
yopathy. Fenofibrate does not affect statin glucuronida-
ion or inhibit CYP 2C8 and may be a safer fibrate choice.
Data from approximately 1,000 subjects who received
enofibrate concomitantly with a statin in the FIELD
Fenofibrate Intervention and Event Lowering in Diabetes)
rial suggest the combination does not significantly increase
isk of myopathy in low-risk diabetic patients (63). The
ngoing ACCORD (Action to Control Cardiovascular
isk in Diabetes) trial will provide important insight into
he additive cardiovascular risk reduction benefit and safety
f fenofibrate when added to moderate-dose simvastatin
herapy in a diabetic population.
Unfortunately, very little data are available for the com-
ination of fenofibrate with the highest doses of statins, and cuch therapy should be pursued only with extreme caution
fter establishing safety and efficacy at lower statin doses.
riple Drug Therapy
he average untreated LDL level for men with CHD is
pproximately 140 mg/dl (64). A 60% reduction in LDL,
hich could be achieved on average with ezetimibe 10 mg
lus atorvastatin 80 mg or rosuvastatin 20 mg, would result
n an LDL level of 84 mg/dl. About half of very high-risk
atients would therefore need the addition of a third (or
ourth) therapy to achieve the additional 17% reduction in
DL needed to reach the optional goal of 70 mg/dl. The
afety of triple-drug combination therapy has been formally
valuated in only 1 randomized trial with a moderate dose of
tatin (65). Lovastatin 40 mg combined with niacin 200 mg
nd colestipol 20 g was evaluated in a cross-over trial in 29
iddle-aged men with CHD. This regimen resulted in 54%
o 60% reduction in LDL, depending on the niacin formu-
ation. Only 21% of subjects reported the regimen was “very
asy” to take, although 79% thought it was “fairly easy.” The
rimary adverse effects were cutaneous, which were less
hen sustained release niacin formulations were used. No
ata on laboratory abnormalities or musculoskeletal com-
laints was reported. Low-density lipoprotein apheresis is
he only other option for lowering LDL 65% in CHD
atients (66), although the vast majority of insurers cur-
ently limit reimbursement to those with LDL levels 200
g/dl despite maximal tolerated therapy.
onclusions
ince many patients with CHD or its equivalent will need
50% reduction in LDL to achieve the LDL goal 100
g/dl, it is reassuring that therapy with the highest doses of
torvastatin, simvastatin, and rosuvastatin appear to be
ell-tolerated in properly selected subjects. Low rates of
erious musculoskeletal (0.6%) or hepatic (1.3%) ad-
erse effects have occurred in randomized event trials with
igher rates of persistent hepatic transaminase elevations
ccurring with atorvastatin 80 mg and higher rates of
yopathy and rhabdomyloysis occurring with simvatatin 80
g. Achievement of the more aggressive optional LDL goal
70 mg/dl should be reserved for the very highest-risk
atients who are most likely to experience benefit and least
ikely to experience toxicity. Although high-dose statin
herapy or combination treatment will most likely be nec-
ssary to achieve an LDL level 70 mg/dl, the long-term
afety of other LDL, non-HDL, or triglyceride-lowering
herapies added on to high-dose statin monotherapy has not
een well established. Ezetimibe and coleselvelam appear
nlikely to increase the risk of myopathy when used in
ombination with a high-dose statin; however, rates of
epatic enzyme elevation are slightly increased. Although
he combination of niacin or fenofibrate with moderate-
ose statins appears to be reasonably safe, the safety of
ombination with high-dose statins has yet to be deter-
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May 1, 2007:1753–62 Aggressive Lipid-Lowering Safetyined. To enhance patient outcomes, clinicians need to be
ware of specific patient characteristics, such as advancing
ge, gender, body mass index, diminished glomerular filtra-
ion rate, and other characteristics that predict muscle and
epatic statin toxicity, especially when considering the use
f high-dose statin or combination therapy.
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